The second study showed that omadacycline was noninferior to linezolid in acute bacterial skin and skin-structure infections.
Nuzyra, an aminomethylcycline (related to tetracycline antibiotics), is designed to overcome tetracycline resistance and has broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria, and other drug-resistant strains.
Phase 3 studies investigating safety, tolerability, and immunogenicity in both adults and children are currently underway.
Patients who either are currently or have recently taken benzodiazepines may have an increased risk for pneumonia.
A shift toward personalized medicine in pneumonia management would involve refining the diagnostic categories to include viral pneumonia, bacterial pneumonia, and noninfectious respiratory disease.
Patients diagnosed with community-acquired pneumonia with higher levels of fibroblast growth factor-21 may have higher mortality rates and longer hospitalizations.
Diagnosing coinfection in pneumonia can be challenging because of timing of the sample collection and false-negative results when the viruses replicate in the lower respiratory tract.
Guideline-concordant prescribing trends in pediatric community-acquired pneumonia appear to be lagging behind in non-children's hospitals compared with children's hospitals.
The number of clinical pneumonia episodes in children younger than 5 years of age was reduced by 22% in developing countries.
Adults hospitalized for pneumonia who received an influenza vaccination during their stay were less likely to seroconvert if they had diabetes, bacterial detection, baseline seropositive titers for influenza B, or influenza vaccination in the previous season.
Nabriva Therapeutics announced the submission of 2 NDAs to the FDA for the oral and IV formulations of lefamulin for the treatment of community-acquired bacterial pneumonia.
A marked and rapid reduction in PCV13 serotype, the most common antibiotic-nonsusceptible S pneumoniae, carriage was observed in both ethnic populations included in this study.
Previous results stated that Legionella pneumonia characteristics may not differ between individuals with HIV and individuals who do not have HIV.
Patients undergoing evaluation for ventilator-associated pneumonia who had an alveolar neutrophil percentage 90% for bacterial pneumonia.
Increases in the relative rates of culture negative pneumonia that required hospitalization or emergency department visits were significantly associated with increased concentrations of fine particulate air pollution.
Treating severe community-acquired pneumonia with a combination of corticosteroids and antibiotics may be a cost-effective strategy.
Invasive pneumococcal disease was significantly higher in premature infants than in infants born at term.
A meta-analysis of case-control studies supports the use of the 13-valent pneumococcal conjugate vaccine in children as it protects against serotype 3.
Compared with idiopathic pulmonary fibrosis, nonhoneycomb hypersensitivity pneumonitis phenotypes are associated with greater improvements in percent-predicted forced vital capacity.
Patients with bacterial pneumonia are at higher risk for major adverse cardiovascular events within 90 days compared with patients with viral pneumonia.
Hands can be vehicles for transmission of pneumococcus and lead to acquisition of nasopharyngeal colonization.
The risk of having a healthcare-associated infection was 16% lower in 2015 than in 2011.
The CHEST Expert Cough Panel agreed on cough, dyspnea, pleural pain, sweating, shivers, aches, temperature of ≥38°C, tachypnea, and new and localizing chest examination signs as clinical symptoms as criteria suggestive of pneumonia in outpatient adults.
Survey finds variance in provider knowledge of adult pneumococcal vaccine recommendations.
Significant associations were seen between increased average prenatal carbon monoxide and reduced time to peak tidal expiratory flow to expiratory time, increased respiratory rate, and increased minute ventilation.
Antipseudomonal combination therapy has shown poorer efficacy than antipseudomonal monotherapy in individuals with suspected pseudomonal pneumonia.
The burden of childhood and infant pneumonia can be effectively reduced through the use of the pneumococcal Haemophilus influenzae protein D conjugate vaccine.
PCV13 in adults age <65 years with diabetes could reduce a substantial number of pneumonia hospitalizations.
The use of fluoroquinolones in stable patients with community-acquired pneumonia can be reduced with stewardship programs that share antibiotic use data and provide guidance for step-down therapy.
The FDA has approved Nuzyra for the treatment of adult patients with CABP and acute bacterial skin and skin structure infections.